Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 5/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 3/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604385 | 0.91 | ACP3 (0.41) | ACP3KDM4EALDH1A1HSD17B10GSK3B | |
| SCHEMBL7609392 | 0.90 | ACP3 (0.41) | ACP3KDM4EALDH1A1HSD17B10MMP1 | |
| SCHEMBL7604545 | 0.84 | ACP3 (0.46) | ACP3PPARGPPARAKDM4EALDH1A1 | |
| Nafcaproic Acid SCHEMBL2109457 | 0.81 | ACP3 (0.45) | ACP3PPARGPPARAKDM4EALDH1A1 | |
| SCHEMBL7603971 | 0.80 | SLC6A2 (0.39) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL7610440 | 0.78 | PTPN1 (0.46) | KDM4EMMP1 | |
| SCHEMBL8060087 | 0.75 | IDO1 (0.40) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL7607484 | 0.75 | ACP3 (0.45) | ACP3PPARGPPARAKDM4EALDH1A1 | |
| SCHEMBL7609446 | 0.75 | ACP3 (0.42) | ACP3PPARGPPARAKDM4EALDH1A1 | |
| SCHEMBL7611154 | 0.75 | ACP3 (0.42) | ACP3PPARGPPARAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002515040-A | — | — | 2002-05-21 | — | — | JP | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |